Literature DB >> 8621362

A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems.

Y Iso1, T Irie, Y Nishino, K Motokawa, Y Nishitani.   

Abstract

The synthesis and biological activity of (1R,5S,6S)-2-[(3S,5S)-5-substituted pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1- methylcarbapen-2-em-3-carboxylic acids are described. These compounds exhibit potent antibacterial activity against a wide range of both Gram-positive and Gram-negative bacteria including Pseudomonas aeruginosa. Of these new carbapenems, (1R,5S,6S)-2-[(3S,5S)-5-sulfamoylaminomethyl pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarb apen- 2-em-3-carboxyli c acid (S-4661) showed the most potent and well balanced activity and was selected as a candidate for further evaluation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621362     DOI: 10.7164/antibiotics.49.199

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

1.  Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to beta-lactams due to reduced expression of the ampC beta-lactamase.

Authors:  N Masuda; E Sakagawa; S Ohya; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  In vitro antimicrobial activity of doripenem, a new carbapenem.

Authors:  Yigong Ge; Matthew A Wikler; Daniel F Sahm; Renée S Blosser-Middleton; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

Authors:  M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa.

Authors:  N Masuda; E Sakagawa; S Ohya; N Gotoh; H Tsujimoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa.

Authors:  N Masuda; N Gotoh; C Ishii; E Sakagawa; S Ohya; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

9.  In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.

Authors:  Chris M Pillar; Mohana K Torres; Nina P Brown; Dineshchandra Shah; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

10.  Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.

Authors:  Shazad Mushtaq; Yigong Ge; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.